Table 4.
MZL-IPI risk stratification analysis.
| (A) PFS | ||||
|---|---|---|---|---|
| Group | n (%) | 5-yr PFS% | HR (95%CI) | P |
| Low (0) | 52 (35.4) | 85.5 | ||
| Int. (1-2) | 81 (55.1) | 73.6 | 1.520 (0.6511-3.546) | 0.333 |
| High (3-5) | 14 (9.5) | 55 | 5.529 (1.234-24.76) | 0.025 |
| High vs. Int. | 2.610 (0.728-9.358) | 0.141 | ||
| (B) OS | ||||
| Group | n (%) | 5-yr OS% | HR (95%CI) | P |
| Low (0) | 52 (35.4) | 95.1 | ||
| Int. (1-2) | 81 (55.1) | 82.8 | 2.031 (0.6451-6.396) | 0.226 |
| High (3-5) | 14 (9.5) | 69.6 | 8.940 (1.104-72.39) | 0.04 |
| High vs. Int. | 2.835 (0.5304-15.16) | 0.223 | ||
MZL-IPI, marginal zone lymphoma-international prognostic index; PFS, progression-free survival; OS, overall survival; Int., Intermediate.